Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALZNthis companyAlzamend Neuro Inc	$1.40	-0.43×	5.19×	0×	-0.36×	-113.5%	0.0%	0.0%	0.0%	-1196.4%	-1195.7%	-212.1%	0×	0.08×	1,324.5×	1.31×	0.0%	1	-12.93	2	C
ACXPAcurx Pharmaceuticals, Inc.	$1.08	-0.47×	0.71×	0×	0.48×	374.0%	0.0%	0.0%	0.0%	-151.2%	-153.6%	-181.9%	0×	0.95×	0×	3.18×	0.0%	2	-10.22	2	B-
APREAprea Therapeutics, Inc.	$0.53	-0.44×	0.45×	0×	0.72×	335.0%	0.0%	0.0%	0.0%	-101.3%	-100.5%	-231.2%	0×	1.16×	0×	5.63×	0.0%	3	-10.16	2	C+
BCDABioCardia, Inc.	$0.95	-1.02×	9.31×	0×	-0.82×	-76.9%	0.0%	0.0%	0.0%	-919.3%	-581.7%	-89.3%	0.59×	0.25×	0×	1.12×	0.0%	1	-51.25	2	C
CDIOCardio Diagnostics Holdings, Inc.	$1.80	-0.73×	0.68×	320.16×	-0.05×	34.3%	100.0%	-43737.5%	-43832.5%	-93.2%	-84.5%	-124.6%	0.1×	0.73×	-438.08×	9.79×	0.0%	1	-1.62	3	B
CELZCreative Medical Technology Holdings, Inc.	$0.64	-0.78×	0.62×	778.38×	0.42×	371.4%	63.4%	-102380.2%	-99916.8%	-79.8%	-81.5%	-125.4%	0×	1.2×	0×	25.97×	0.0%	1	-10.71	2	B-
Peer median	—	-0.73×	0.68×	0×	0.42×	335.0%	0.0%	0.0%	0.0%	-101.3%	-100.5%	-125.4%	0×	0.95×	0×	5.63×	0.0%	1	-10.22	2	—